All studies
AuthorisedPhase I and Phase II (Integrated)- OtherInterventional

A Global, Open-Label, Phase I/II Trial, to Evaluate Safety, Tolerability, Pharmacodynamic and Preliminary Efficacy of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, is a rare genetic condition where the body cannot properly break down certain complex sugars. Over time, these sugars build up and cause damage, particularly to the brain and nervous system. This study is testing an experimental medicine called JR-446. The main goal is to check how safe it is and whether it causes any side effects, especially during or after it is given through a drip (infusion). Researchers will also measure whether the medicine lowers the levels of built-up sugars in the blood, urine, and spinal fluid. In addition, doctors will look at brain scans and track everyday development to see if the treatment helps protect the brain. People of any age with a confirmed diagnosis of MPS IIIB may be able to take part.

At a glance

Status
Authorised
Phase
Phase I and Phase II (Integrated)- Other
Sponsor
Jcr Pharmaceuticals Co. Ltd.
Enrolment target
2
Start
11 Nov 2026

What is this study about?

Mucopolysaccharidosis type IIIB (MPS IIIB), often called Sanfilippo syndrome type B, is a rare inherited condition. In people with MPS IIIB, the body is missing an essential enzyme needed to recycle natural complex sugars. Without this enzyme, these sugars build up inside cells, especially in the brain. Over time, this leads to difficulties with learning, behaviour, movement, and sleep. Currently, there are very limited treatment options for this condition, and care mostly focuses on managing symptoms.

This clinical study is testing a new experimental drug named JR-446. Scientists have designed JR-446 to replace the missing enzyme and help clear the harmful sugar build-up. An important feature of this research is seeing whether the treatment can reach the brain, where it is needed most to help protect nerve cells.

Because this is an early-phase trial, the main priority is safety. Doctors want to see how well patients tolerate the medicine and whether it causes any unwanted reactions. They will also look for early signs that the treatment is working by checking sugar levels in body fluids and seeing if it helps support normal growth and brain health.

Key takeaways

  • Testing a new medicine called JR-446 for children and adults with MPS IIIB.
  • The primary goal is to make sure the drug is safe and well tolerated.
  • All participants receive the study medicine; no one is given a placebo.
  • Tests will include regular infusions, blood and urine checks, brain MRIs, and spinal fluid tests.
  • Taking part is completely voluntary and will not affect standard healthcare.

Who may be eligible?

This study is open to both males and females of any age who have a confirmed diagnosis of MPS IIIB (Sanfilippo syndrome type B). Because this condition is so rare, doctors want to learn how the treatment affects people at different stages of life.

To join, participants will need to undergo a full medical assessment. The study team will check general health, heart function, and organ health to ensure taking part is as safe as possible.

Some individuals may not be able to take part—for example, if they have other serious medical conditions that could make the trial unsafe, or if they have recently received other experimental treatments. Your hospital specialist or the study team can review detailed medical records to see if you or your child meet the criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Confirmed medical diagnosis of MPS IIIB (Sanfilippo syndrome type B)
  2. Any age (children and adults are both considered)
  3. Able to attend regular hospital visits for infusions and health checks
  4. Willing to undergo monitoring, such as blood tests and MRI scans
  5. Not currently taking part in another conflicting clinical trial
Answer every question to see your result.

What does participation involve?

Taking part involves receiving the study medicine, JR-446, given into a vein through a slow drip (an infusion). Because this is an 'open-label' study, all participants will receive the active medicine rather than a dummy drug (placebo).

Participants will need to visit the clinic regularly for treatment and health checks. During these visits, the medical team will carry out standard tests, including blood and urine tests, heart traces (ECGs), and checks of blood pressure and temperature. Doctors will also collect small samples of spinal fluid (using a procedure called a lumbar puncture) to see how much medicine reaches the central nervous system.

Over the course of the study—which tracks key outcomes for at least 53 weeks (about one year)—participants will also have MRI brain scans to look at brain structure, height and weight measurements to track growth, and developmental questionnaires to see how daily skills are progressing.

Potential risks and benefits

There is no guarantee that taking part will improve health or symptoms, but the study medicine might help reduce the build-up of harmful sugars and protect the brain. The main risks involve potential side effects from the drug itself or reactions during the infusion, such as fever, rash, or breathing difficulties. Tests like blood draws and lumbar punctures may also cause temporary discomfort or bruising. Safety is closely monitored at every visit, and taking part is entirely voluntary—families have the right to withdraw from the trial at any time without it affecting their usual NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is JR-446?

JR-446 is an experimental enzyme replacement medicine designed to break down the natural sugars that build up in people with MPS IIIB.

Will anyone receive a placebo (dummy drug)?

No. This is an open-label study, meaning every person who takes part will receive the actual study medicine.

How long does the study last?

The main parts of the trial track progress over at least 53 weeks (about one year), with regular clinic visits for infusions and tests.

Does my child have to be a specific age?

No. The trial is open to people of all ages who have a confirmed diagnosis of MPS IIIB.

What happens if we want to stop taking part?

You are free to leave the study at any point. Your decision will not change or harm the standard medical care you receive.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.